Iwer Baecker, MD of Bayer Ireland, outlines the Irish affiliate’s impressive growth in the past few years, the strategy of New Bayer and how it comes into play in Ireland, as well as how Ireland’s small size is not a constraint but rather a huge opportunity to be taken advantage of.
The past 12 months saw Bayer reorganize itself, notably with the spin-off of its material science unit and the integration of three divisions and an overall Life Science focus. What has this meant for the Irish affiliate?
"Since the end of 2014, Bayer has been one of the top ten pharma companies in Ireland, from number 15 or 16 in 2013, and the top five in the life sciences companies."
